Preoperative radiochemotherapy in the treatment of advanced oral cancer: outcome of 276 patients

J Craniomaxillofac Surg. 2009 Sep;37(6):344-7. doi: 10.1016/j.jcms.2008.11.012. Epub 2009 Jun 13.

Abstract

Introduction: The aim of this study was to review survival and locoregional control in patients with advanced oral and oropharyngeal squamous cell carcinoma treated by multimodal therapy with preoperative radiochemotherapy and radical surgery.

Material: Retrospective cohort study.

Methods: Included in this analysis are 276 consecutive patients with UICC disease stages III and IV (T2: 13.0%; T3: 16.7%; T4: 70.3%; N0: 29.7%; N1: 20.3%; N2: 45.3%; N3: 4.7%; stage III: 16.3%; stage IV: 83.7%). All patients received preoperative radiochemotherapy (50Gy, Mitomycin and 5-Fluorouracil) and radical locoregional resection.

Results: Median surveillance period was 101.4 months (24-202 months). 5-year overall survival probability was 53.9%. 5-year local control probability was 70.2%.

Conclusion: These results underline the reliability of preoperative treatment of patients with oral and oropharyngeal cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Squamous Cell / drug therapy*
  • Carcinoma, Squamous Cell / pathology
  • Carcinoma, Squamous Cell / radiotherapy*
  • Carcinoma, Squamous Cell / surgery
  • Cohort Studies
  • Female
  • Fluorouracil / therapeutic use
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Mitomycin / therapeutic use
  • Mouth Neoplasms / drug therapy*
  • Mouth Neoplasms / pathology
  • Mouth Neoplasms / radiotherapy*
  • Mouth Neoplasms / surgery
  • Neoadjuvant Therapy*
  • Neoplasm Recurrence, Local
  • Neoplasm Staging
  • Oropharyngeal Neoplasms / drug therapy
  • Oropharyngeal Neoplasms / pathology
  • Oropharyngeal Neoplasms / radiotherapy
  • Oropharyngeal Neoplasms / surgery
  • Preoperative Care*
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Mitomycin
  • Fluorouracil